Were Carl Dambkowski’s Oruka Therapeutics (ORKA) share sales under a Rule 10b5-1 plan?

Yes. A Form 4 footnote states these Oruka Therapeutics share sales were effected pursuant to a Rule 10b5-1 trading plan. Such pre-arranged plans allow insiders to systematically sell shares according to preset instructions, helping separate trades from nonpublic information.

Oruka Therapeutics (ORKA) director sells 35,000 shares under Rule 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Oruka Therapeutics director Carl Dambkowski reported planned share sales. He sold 22,417 shares of common stock on June 11, 2026 at a weighted average price of $70.1343 per share, followed by 12,583 shares on June 12, 2026 at $70.1090 per share in open-market transactions. According to a footnote, these sales were made under a pre-arranged Rule 10b5-1 trading plan. After the transactions, he directly holds 38,743 Oruka Therapeutics shares.

Insights

Director executes pre-planned sales totaling 35,000 shares, retains sizable stake.

Carl Dambkowski, a director of Oruka Therapeutics, executed two open-market sales under a disclosed Rule 10b5-1 trading plan. He sold a combined 35,000 shares of common stock at weighted average prices slightly above $70 per share.

Form 10b5-1 plans are set up in advance and are designed to separate trading from day-to-day information flow. After these transactions, Dambkowski continues to hold 38,743 shares directly, indicating that a meaningful equity position remains.

The filing does not provide company-level metrics such as market capitalization or shares outstanding, so the relative size of this sale versus Oruka’s total equity base cannot be assessed from this document alone.

Insider Trade Summary 10b5-1

Net Seller: 35,000 shares ($2,454,382)

Net Sell 2 txns

Insider Dambkowski Carl

Role null

Sold 35,000 shs ($2.45M)

Type	Security	Shares	Price	Value
Sale	Common Stock	12,583	$70.109	$882K
Sale	Common Stock	22,417	$70.1343	$1.57M

Holdings After Transaction: Common Stock — 38,743 shares (Direct, null)

Footnotes (1)

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.65, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive.

Key Figures

Shares sold June 11, 2026: 22,417 shares Price June 11, 2026: $70.1343/share Shares sold June 12, 2026: 12,583 shares +3 more

6 metrics

Shares sold June 11, 2026 22,417 shares Open-market sale of common stock

Price June 11, 2026 $70.1343/share Weighted average sale price

Shares sold June 12, 2026 12,583 shares Open-market sale of common stock

Price June 12, 2026 $70.1090/share Weighted average sale price

Total shares sold 35,000 shares Net shares sold across both transactions

Shares held after transactions 38,743 shares Direct ownership after June 12, 2026 sale

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale

3 terms

Rule 10b5-1 trading plan financial

"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/12/2026 - 04:36 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dambkowski Carl

(Last)

(First)

(Middle)

C/O ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK

CALIFORNIA

94025

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/11/2026		S⁽¹⁾		22,417	D	$70.1343⁽²⁾	51,326	D
Common Stock	06/12/2026		S⁽¹⁾		12,583	D	$70.109⁽³⁾	38,743	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.65, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive.

	/s/ Paul Quinlan, as attorney-in-fact for Carl Dambkowski	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Oruka Therapeutics (ORKA) report for Carl Dambkowski?

Oruka Therapeutics director Carl Dambkowski reported two open-market sales totaling 35,000 common shares. He sold 22,417 shares on June 11, 2026 and 12,583 shares on June 12, 2026, according to the Form 4 insider trading report.

At what prices did Carl Dambkowski sell Oruka Therapeutics (ORKA) shares?

Carl Dambkowski’s Form 4 shows weighted average sale prices around $70 per share. He sold 22,417 shares at a weighted average of $70.1343 and 12,583 shares at a weighted average of $70.1090 in open-market transactions.

How many Oruka Therapeutics (ORKA) shares does Carl Dambkowski hold after the sales?

After the reported transactions, Carl Dambkowski directly holds 38,743 Oruka Therapeutics common shares. The filing lists this post-transaction balance following the June 12, 2026 open-market sale of 12,583 shares under his pre-arranged trading plan.

How many Oruka Therapeutics (ORKA) shares did Carl Dambkowski sell in total?

The Form 4 reports that Oruka Therapeutics director Carl Dambkowski sold a combined 35,000 common shares. He sold 22,417 shares on June 11, 2026 and 12,583 shares on June 12, 2026, both as open-market transactions at weighted average prices above $70.